NCT04607772 2025-10-03Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)Karyopharm Therapeutics IncPhase 1/2 Withdrawn